Extended Data Fig. 3: CSF ctDNA status implicated LM development. | Nature Medicine

Extended Data Fig. 3: CSF ctDNA status implicated LM development.

From: Cerebrospinal fluid circulating tumor DNA profiling for risk stratification and matched treatment of central nervous system metastases

Extended Data Fig. 3: CSF ctDNA status implicated LM development.The alternative text for this image may have been generated using AI.

a, Comparison of proportion of developing LM after two-year follow up for patients who had negative CSF cytology & positive CSF ctDNA detection (16/33, 48.5%) and negative CSF cytology & positive CSF ctDNA detection (12/51, 23.5%) at baseline. Only patients with BM at baseline were included with confirmed CSF cytological results and brain MRI. Negative CSF cytology indicated that no tumor cell was found in CSF. Fisher’s exact test with two-sided P value. b, Comparison of lead time of LM diagnosis for patients who had negative CSF cytology & positive CSF ctDNA detection (n = 18, median time, 202 days) and negative CSF cytology & positive CSF ctDNA detection (n = 16, median time, 417 days) at baseline. Follow up time was not restricted to two years in this analysis. Wilcoxon rank sum test with two-sided P value.

Source data

Back to article page